These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 34649240)
1. Correlation between NEN Bone Metastasis Performance and Tumor Proliferation: 112 Cases of [68Ga]Ga-DOTA-TATE Result Analysis. Xie Q; Lu M; Zhai S; Guo R; Du C; Zhu H; Li N; Yu J; Yang Z Neuroendocrinology; 2022; 112(7):666-672. PubMed ID: 34649240 [TBL] [Abstract][Full Text] [Related]
2. Detection of Bone Metastases by Tian R; Xie Q; Yu F; Du C; Yao X; Zang S; Zhang C; Zhang P; Shao G; Yang Z; Wang F; Yu J Contrast Media Mol Imaging; 2022; 2022():1750132. PubMed ID: 36447752 [TBL] [Abstract][Full Text] [Related]
3. The Correlation Between [ Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708 [TBL] [Abstract][Full Text] [Related]
4. The Application of 68Ga-Somatostatin Analog and 18F-FDG PET/CT for Bone Metastasis from Neuroendocrine Tumors. Bai L; Xu J; Xu X; Zhang J; Liu X; Hu S; Chen J; Song S Neuroendocrinology; 2024; 114(8):775-785. PubMed ID: 38824926 [TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
6. PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer. Gofrit ON; Frank S; Meirovitz A; Nechushtan H; Orevi M Clin Nucl Med; 2017 Jan; 42(1):1-6. PubMed ID: 27775942 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [ Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145 [TBL] [Abstract][Full Text] [Related]
8. Response to Single Low-dose Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731 [No Abstract] [Full Text] [Related]
9. Somatostatin Receptor Imaging in Mice with Difference Positive Rate of SSTR2. Xie Q; Zhou W; Meng X; Ding J; Li D; Lu M; Yang Z; Yu J Neuroendocrinology; 2024; 114(9):848-855. PubMed ID: 37926096 [TBL] [Abstract][Full Text] [Related]
10. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108 [TBL] [Abstract][Full Text] [Related]
11. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Abdulrezzak U; Kurt YK; Kula M; Tutus A Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719 [TBL] [Abstract][Full Text] [Related]
12. Clinical and Prognostic Value of PET/CT Imaging with Combination of Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780 [TBL] [Abstract][Full Text] [Related]
13. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Haug A; Auernhammer CJ; Wängler B; Tiling R; Schmidt G; Göke B; Bartenstein P; Pöpperl G Eur J Nucl Med Mol Imaging; 2009 May; 36(5):765-70. PubMed ID: 19137293 [TBL] [Abstract][Full Text] [Related]
14. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. Karls S; Gold R; Kravets S; Wang Y; Cheng S; Perez K; Chan J; Jacene H Ann Nucl Med; 2021 Sep; 35(9):1066-1077. PubMed ID: 34146243 [TBL] [Abstract][Full Text] [Related]
15. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis. Kunikowska J; Pawlak D; Kolasa A; Mikołajczak R; Królicki L Clin Nucl Med; 2014 Oct; 39(10):855-61. PubMed ID: 25072928 [TBL] [Abstract][Full Text] [Related]
16. Biodistribution and first clinical results of Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas. Ambrosini V; Campana D; Polverari G; Peterle C; Diodato S; Ricci C; Allegri V; Casadei R; Tomassetti P; Fanti S J Nucl Med; 2015 Dec; 56(12):1843-8. PubMed ID: 26405169 [TBL] [Abstract][Full Text] [Related]
18. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643 [TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222 [TBL] [Abstract][Full Text] [Related]
20. The added value of Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]